Tracer library / [47Sc]Sc-PSMA-617

Structure of PSMA-617 (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 122706786

[47Sc]Sc-PSMA-617

Also written as PSMA-617; Pluvicto

Radionuclide: Sc-47 t½ 4823.8 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: PSMA-targeting urea-based small molecule (PSMA-617)
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 41705479
Clinical application: Prostate cancer PMID 37630292
Theranostic pair: [111In]In-PSMA-617

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	>99%	>99%	PSMA-617	41705479 2026 Mol Pharm

Need this precursor?We can point you to suppliers for [47Sc]Sc-PSMA-617, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Compound class inferred from precursor name (not stated outright) -- PMID 41705479: 'PSMA-617'. Stage set/updated at stage 23 from PMID 41705479: '[47Sc]Sc-PSMA-617 was used in PET imaging studies in LNCaP or PC-3 tumor models'.